As shown in Figure 1, treatment of platelets with the Ig fractions from patients with AIS during COVID-19, as well as with polyclonal anti-β2-GPI IgG, induced a significant increase of both phospho-ERK (Figure 1A) and phospho-p38 (Figure 1B) expression, as compared to control untreated platelets or platelets treated with Ig fractions from healthy donors, non-COVID-19 stroke patients and COVID-19 patients without vascular thrombosis (p < 0.0001). This evidence concerns the gene MAPK14 and COVID-19.